Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib in Localized Prostate Cancer Before Prostatectomy
NCT03274778Withdrawn
- Sponsor
- Istituto Oncologico della Svizzera Italiana
- Start
- Sep 2017
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of ruxolitinib in prostate cancer (PCa), sponsored by Istituto Oncologico della Svizzera Italiana. Primary endpoint: Tumor immune response at 9 weeks. Planned start Sep 2017; status: withdrawn.
02
Drugs
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT03274778.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03274778.